One potential explanation for the enhanced tissue distribution but improved tolerability for nab-paclitaxel is that paclitaxel exposure in normal tissues is reduced whereas more paclitaxel is delivered into tumor via albumin transport pathways, as demonstrated by results in preclinical tumor xenograft models [7, 42]. The gene discussed is ALB; the disease is neoplasm.